AstraZeneca says its China operations president under investigation
Adds detail on share decline, paragraph 1, on separate investigation of other employees that began in September, paragraph 7, and context in final two paragraphs
By Maggie Fick
Oct 30 (Reuters) -AstraZeneca's AZN.L China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday, sending its shares down as much as 5.3% and making it the biggest loser on London's FTSE 100.
It was not immediately clear whether the executive Leon Wang was in the custody of the Chinese government. When asked about Wang's whereabouts, a company spokesperson only reiterated that the executive was under investigation.
The Anglo-Swedish company has for years had one of the strongest market positions among western drugmakers in China, the world's No.2 pharmaceuticals market behind the United States. It has invested heavily in the country, announcing plans last year to build a $450 million factory and more recently signing a number of licensing deals with Chinese companies.
In a statement, the drugmaker said its Chinese operations were "under the leadership of the current general manager of AstraZeneca China," without providing further details.
"If requested, AstraZeneca will fully cooperate with the investigation", the statement read.
AstraZeneca shares were down 5.2% at 1429 GMT.
In September, China detained five of AstraZeneca's current and former employees for questioning. At the time, Bloomberg News reported that the employees were detained for questioning about potential illegal activities.
The company has not given details about the detention in September and a spokesperson had no comment on Wednesday on the status of the employees being held.
Other foreign drugmakers have been subject to anti-graft investigation in China.
Last year, multinational pharma companies including South African drugmaker Aspen APNJ.J suffered business disruptions and lost orders from hospitals in China after Beijing intensified an anti-corruption drive in the nation's healthcare sector.
Reporting by Maggie Fick in London;
Additional reporting by Yadarisa Shabong in Bengaluru and Ludwig Burger in Frankfurt;
Editing by Krishna Chandra Eluri, Tomasz Janowski and Barbara Lewis
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
